IDXX

SEC source: 0001567619-19-021041 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 962,964

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $264.26 to a high of $265.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-021041 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 965,982

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $263.195 to a high of $264.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-021041 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 978,747

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $262.19 to a high of $263.19 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 10

AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000,754

F10 · price: Represents the weighted average price of the shares sold ranging from a low of 266.1150 to a high of $267.05 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 9

AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,012,548

F9 · price: Represents the weighted average price of the shares sold ranging from a low of 265.00 to a high of $266.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 8

AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,016,387

F8 · price: Represents the weighted average price of the shares sold ranging from a low of 277.55 to a high of $277.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-020466 · doc1.xml · nonDerivative · entry 2

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · M. Anne Szostak Trust

Disclosed balance after: 2,916

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $279.58 to a high of $280.48 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-020466 · doc1.xml · nonDerivative · entry 1

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · M. Anne Szostak Trust

Disclosed balance after: 3,899

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $278.56 to a high of $279.51 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-020465 · doc1.xml · derivative · entry 2

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,992

Underlying: Common Stock · 27,992 shares

Expires 2029-11-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning November 4, 2020. This option grant was made at an exercise price of 110% of the closing price of Issuer common stock on the grant date.

SEC source: 0001567619-19-020529 · doc1.xml · derivative · entry 12

AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 53,820 shares

Expires 2020-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · shares: The number of derivative securities has been revised to reflect the current number available for the reported transaction.

F13 · price: Not applicable.

F12 · derivative.exercise_date: Grant of option to buy 55,910 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 7

AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,017,687

F7 · price: Represents the weighted average price of the shares sold ranging from a low of 281.515 to a high of $281.90 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 6

AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,020,671

F6 · price: Represents the weighted average price of the shares sold ranging from a low of $280.05 to a high of $280.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 5

AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,024,073

F5 · price: Represents the weighted average price of the shares sold ranging from a low of $279.01 to a high of $280.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,025,964

F4 · price: Represents the weighted average price of the shares sold ranging from a low of $280.17 to a high of $280.63 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,030,211

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $279.16 to a high of $280.15 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,056,409

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $278.155 to a high of $279.15 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,079,784

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 22 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2019.

SEC source: 0001567619-19-020252 · doc1.xml · nonDerivative · entry 1

ESSIG STUART · CIK 0001187574 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 792

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-19-020253 · doc1.xml · nonDerivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,812

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($6,250.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-19-020254 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,251

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-19-017893 · doc1.xml · derivative · entry 2

SAMAD SAM · CIK 0001694295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,025

Underlying: Common Stock · 1,025 shares

Expires 2029-08-31

F1 · security: This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from his election to the IDEXX Laboratories, Inc. Board of Directors on July 16, 2019 until the 2020 annual meeting of stockholders.

F3 · derivative.exercise_price: August 30, 2019 closing price of Issuer common stock on the NASDAQ Global Select Market.

F5 · price: Not applicable.

F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests in one installment on May 6, 2020.

SEC source: 0001567619-19-017893 · doc1.xml · derivative · entry 1

SAMAD SAM · CIK 0001694295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 293

Underlying: Common Stock · 293 shares

Expires not disclosed

F1 · security: This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from his election to the IDEXX Laboratories, Inc. Board of Directors on July 16, 2019 until the 2020 annual meeting of stockholders.

F2 · derivative.exercise_price: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2020 annual meeting of stockholders or May 6, 2020, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F5 · price: Not applicable.

F2 · derivative.exercise_date: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2020 annual meeting of stockholders or May 6, 2020, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F2 · derivative.expiration_date: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2020 annual meeting of stockholders or May 6, 2020, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001567619-19-017356 · doc1.xml · nonDerivative · entry 1

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,696

SEC source: 0001567619-19-017053 · doc1.xml · nonDerivative · entry 2

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Sophie Vandebroek Revocable Trust

Disclosed balance after: 6,000

F1 · ownership.nature: The shares are held by the Sophie Vandebroek Revocable Trust datedd June 28, 2019, of which the Reporting person is grantor, a trustee and a beneficiary.

SEC source: 0001567619-19-017053 · doc1.xml · nonDerivative · entry 1

Vandebroek Sophie V. · CIK 0001442078 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,178

SEC source: 0001567619-19-016395 · doc1.xml · nonDerivative · entry 1

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,315

F1 · balance_after: Includes 20 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 28, 2019.

SEC source: 0001567619-19-016171 · doc1.xml · derivative · entry 6

MAZELSKY JAY · CIK 0001556270 · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,306 shares

Expires 2019-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy 5,255 shares of Issuer common stock that became exercisable in five annual installments beginning September 1, 2013 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-016171 · doc1.xml · derivative · entry 5

MAZELSKY JAY · CIK 0001556270 · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,848 shares

Expires 2019-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy 1,424 shares of Issuer common stock that became exercisable in five annual installments beginning September 1, 2013 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-016171 · doc1.xml · derivative · entry 4

MAZELSKY JAY · CIK 0001556270 · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,824

Underlying: Common Stock · 2,204 shares

Expires 2020-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy 13,014 shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-016171 · doc1.xml · nonDerivative · entry 3

MAZELSKY JAY · CIK 0001556270 · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,628

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-016171 · doc1.xml · nonDerivative · entry 2

MAZELSKY JAY · CIK 0001556270 · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,322

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-016171 · doc1.xml · nonDerivative · entry 1

MAZELSKY JAY · CIK 0001556270 · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,474

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-016394 · doc1.xml · derivative · entry 5

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,820

Underlying: Common Stock · 10,000 shares

Expires 2020-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy 55,910 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-016394 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,025,942

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $273.26 to a high of $273.46 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-016394 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,027,464

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $272.25 to a high of $273.25 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-016394 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,035,942

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-004074 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 911,964

SEC source: 0001567619-19-016170 · doc1.xml · nonDerivative · entry 3

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · M. Anne Szostak Trust

Disclosed balance after: 6,199

SEC source: 0001567619-19-016170 · doc1.xml · nonDerivative · entry 2

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · M. Anne Szostak Trust

Disclosed balance after: 8,699

F1 · price: The 2018 Szostak IDEXX GRAT (the "GRAT") made an annuity payment of the shares of Issuer common stock to the M. Anne Szostak Trust ("Trust"). The reporting person is the settlor of the Trust, the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust.

SEC source: 0001567619-19-016170 · doc1.xml · nonDerivative · entry 1

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · 2018 Szostak IDEXX GRAT

Disclosed balance after: 6,717

F1 · shares: The 2018 Szostak IDEXX GRAT (the "GRAT") made an annuity payment of the shares of Issuer common stock to the M. Anne Szostak Trust ("Trust"). The reporting person is the settlor of the Trust, the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust.

F1 · price: The 2018 Szostak IDEXX GRAT (the "GRAT") made an annuity payment of the shares of Issuer common stock to the M. Anne Szostak Trust ("Trust"). The reporting person is the settlor of the Trust, the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust.

F2 · ownership.nature: The reporting person is the settlor and trustee of the GRAT. The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.

SEC source: 0001567619-19-015977 · doc1.xml · derivative · entry 11

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,820

Underlying: Common Stock · 10,000 shares

Expires 2020-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · price: Not applicable.

F8 · derivative.exercise_date: Grant of option to buy 55,910 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-015977 · doc1.xml · nonDerivative · entry 8

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,025,942

F7 · price: Represents the weighted average price of the shares sold ranging from a low of $264.31 to a high of $265.30 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-015977 · doc1.xml · nonDerivative · entry 7

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,035,942

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-19-016072 · doc1.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,778

SEC source: 0001567619-19-015980 · doc1.xml · derivative · entry 6

MAZELSKY JAY · CIK 0001556270 · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,028

Underlying: Common Stock · 10,000 shares

Expires 2029-08-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Not applicable.

F5 · derivative.exercise_date: Grant of option to buy 13,014 shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-19-015980 · doc1.xml · derivative · entry 5

MAZELSKY JAY · CIK 0001556270 · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,439

Underlying: Common Stock · 1,923 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

F6 · price: Not applicable.

F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

SEC source: 0001567619-19-015980 · doc1.xml · derivative · entry 4

MAZELSKY JAY · CIK 0001556270 · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,116

Underlying: Common Stock · 20,116 shares

Expires 2029-08-04

F6 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning August 5, 2020.

SEC source: 0001567619-19-015980 · doc1.xml · nonDerivative · entry 3

MAZELSKY JAY · CIK 0001556270 · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,270

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $256.28 to a high of $257.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-19-015980 · doc1.xml · nonDerivative · entry 2

MAZELSKY JAY · CIK 0001556270 · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,869

SEC source: 0001567619-19-015980 · doc1.xml · nonDerivative · entry 1

MAZELSKY JAY · CIK 0001556270 · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,270

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes a total of 58 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 29, 2019 and June 28, 2019.